Journey Medical Corporation to Participate in September 2025 Investor Conferences
DERM(NASDAQ:DERM) SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.
Journey Medical Corporation to Present at the Emerging Growth Conference
DERMSCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
DERMSCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.
Journey Medical Q1 EPS $(0.18) Beats $(0.24) Estimate, Sales $13.14M Beat $12.05M Estimate
DERMJourney Medical Promotes Ramsey Alloush, Currently General Counsel, To The Position Of COO
DERMJourney Medical Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi To Treat Rosacea; DFD-29 Achieved The Co-Primary And All Secondary Endpoints With No Significant Safety
DERMWhat's Going On With Journey Medical Stock Today?
DERMJourney Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea.
Journey Medical shares are trading higher after the company announced the preparation of the U.S. launch of its FDA-approved rosacea drug Emrosi.
DERMJourney Medical Prepares US Launch for FDA-Approved Rosacea Drug Emrosi
DERM